Tivozanib
- Generic Name
- Tivozanib
- Brand Names
- Fotivda
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN4O5
- CAS Number
- 475108-18-0
- Unique Ingredient Identifier
- 172030934T
- Background
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapi...
- Indication
适用于治疗既往两种或多种全身治疗后复发或难治性晚期肾细胞癌（RCC）的成年患者。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
Tivozanib Alone Outperforms Lower-Dose Tivozanib-Nivolumab Combo in Metastatic RCC
TiNivo-2 study found no improvement in outcomes when nivolumab was added to tivozanib for metastatic renal cell carcinoma patients who progressed on checkpoint inhibitor therapy. Tivozanib monotherapy showed better median progression-free survival (PFS) than the combination. The study suggests reconsidering ICI rechallenge and supports tivozanib monotherapy as a second-line option.
Related Clinical Trials:
ICI combination rechallenge does not improve outcomes in advanced renal cell carcinoma
TiNivo-2 trial found no improvement in clinical outcomes with nivolumab plus low-dose tivozanib vs. standard-dose tivozanib monotherapy in advanced RCC patients post-ICI treatment, failing to meet primary PFS endpoint. Tivozanib at 1.34 mg supported as second-line therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath